Researchers at Sanford Burnham Prebys and collaborators at the University of Illinois Chicago reported in Science Advances that phosphoinositide kinases PI5P4Ks help regulate cholesterol trafficking to sustain tumor growth in cholesterol-dependent cancers. In mouse studies and human cancer cell models, impairing these enzymes triggered a cholesterol “traffic jam,” starving tumor cells of metabolites needed for proliferation. The work centers on TP53-mutant contexts, where extra cholesterol production is common, and highlights lipid-transport machinery as a potential therapeutic target rather than cholesterol as a broad biomarker. For drug developers, the findings narrow the focus to specific enzymatic regulators of cholesterol movement—an approach that could support next-generation targeted strategies in hard-to-treat subsets such as triple-negative breast cancer and HER2-amplified disease with TP53 disruption.